Exogenous alpha 1-antitrypsin down-regulates SERPINA1 expression

Ahmad Karadagi1, Helene Johansson1, Helen Zemack1, Sandeep Salipalli2, Lisa-Mari Mörk1, Kristina Kannisto3, Carl Jorns1, Roberto Gramignoli3, Stephen Strom3, Knut Stokkeland4,5, Bo-Göran Ericzon1, Danny Jonigk6, Sabina Janciauskiene2, Greg Nowak1*, Ewa C. S. Ellis1*.

1 Division of Transplantation Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden, 2 Department of Respiratory Medicine, Research in Endstage and Obstructive Lung Disease Hannover (BREATHE), Member of the German Center for Lung Research (DZL), Hannover Medical School, Hannover, Germany, 3 Division of Pathology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden, 4 Department of Medicine, Visby Hospital, Visby, Sweden, 5 Department of Medicine, Gastroenterology and Hepatology Unit, Karolinska Institute, Stockholm, Sweden, 6 Institute of Pathology, Hannover Medical School, Hannover, Germany

* These authors contributed equally to this work.

Ewa.Ellis@ki.se

Abstract

The main goal of the therapy with purified human plasma alpha1-antitrypsin (A1AT) is to increase A1AT levels and to prevent lungs from elastolytic activity in patients with PiZZ (Glu342Lys) A1AT deficiency-related emphysema. Potential hepatic gains of this therapy are unknown. Herein, we investigated the effect of A1AT therapy on SERPINA1 (gene encoding A1AT) expression. The expression of SERPINA1 was determined in A1AT or A1AT plus Oncostatin M (OSM) treated primary human hepatocytes isolated from liver tissues from A1AT deficient patients and control liver tissues. In addition, SERPINA1 mRNA was assessed in lung tissues from PiZZ emphysema patients with and without A1AT therapy, and in adherent human peripheral blood mononuclear cells (PBMC) isolated from healthy PiMM donors. In a dose-dependent manner purified A1AT lowered SERPINA1 expression in hepatocytes. This latter effect was more prominent in hepatocytes stimulated with OSM. Although it did not reach statistical significance (P = 0.0539)—analysis of lung tissues showed lower SERPINA1 expression in PiZZ emphysema patients receiving augmentation therapy relative to those without therapy. Finally, exogenously added purified A1AT (1mg/ml) reduced SERPINA1 expression in naïve as well as in lipopolysaccharide (LPS)-stimulated human adherent PBMCs. Exogenous A1AT protein reduces its own endogenous expression. Hence, augmentation with native M-A1AT protein and a parallel reduction in expression of dysfunctional mutant Z-A1AT may be beneficial for PiZZ liver, and this motivates further studies.
**Introduction**

Alpha 1-antitrypsin (A1AT) is an acute phase protein, highly expressed during inflammatory processes and one of the major proteinase inhibitors predominantly synthesized by hepatocytes [1].

The A1AT protein is encoded by the protease inhibitor (Pi) locus on chromosome 14q32.1, as a part of gene cluster called SERPIN supergene [1, 2]. The Z variant of A1AT, which differs from the normal M variant by substitution of Glu342 with Lys (6), is the most prevalent A1AT deficiency (A1ATD) variant among Caucasians, associated with risk for developing early onset lung emphysema and liver disease at any age. The incidence of ZZ A1ATD is 1 in 1 500–5 000 individuals, suggesting that approximately 100 000 subjects in western countries are affected by this mutation [3, 4].

Severe PiZZ A1ATD is associated with about 90% lower level of plasma A1AT (normal level 1–2 mg/ml) that arise not from the lack of protein synthesis but from its intracellular polymerization and accumulation [2]. Various factors can influence the rate of Z-A1AT intracellular and extracellular polymerization, and the retained Z-A1AT polymers in hepatocytes are suggested to contribute to and/or cause liver cell damage with a variable clinical presentation, from neonatal hepatitis to liver cirrhosis with increased risk of hepatocellular carcinoma in adults (10).

A1ATD is an accepted indication for both lung and liver transplantation [3–7]. However, hepatic damage is often overlooked in early preventable stages. Due to organ shortage, A1ATD patients are often not considered for liver transplantation until the manifestation of liver damage and are transplanted only when there is extensive liver disease. Hepatic involvement is mostly considered in neonates as these patients often present with cholestasis and considerable morbidity. However, the acutely ill neonate populations only accounts for a small fraction of A1ATD patients. The majority goes on unnoticed while up to 15% develop cirrhosis and hepatocellular carcinoma as reported by the Swedish autopsy studies [8, 9].

The only specific treatment for patients with A1ATD-related emphysema is intravenous infusions of plasma purified A1AT [4]. The concept behind this therapy is to raise the concentration of A1AT in blood to balance destructive effects of proteases, specifically neutrophil elastase [4, 10]. It has been proposed that therapy with plasma purified A1AT not only normalizes levels of A1AT to inhibit neutrophil elastase activity but also reduces transcriptional levels of neutrophil elastase, and thus may indirectly reduce expression of defective Z-A1AT [11]. Indeed, exogenous A1AT therapy is not recommended for A1ATD patients with liver diseases and its effect on A1ATD liver has not been tested. Therefore, in this study we investigate the potential effects of purified A1AT on SERPINA1 expression in human hepatocytes, circulating mononuclear cells and lung tissue.

**Materials and methods**

**SNP analysis and genotyping**

The included individuals were genotyped using Single Nucleotide Polymorphism (SNP) genotyping TaqMan® assays on a ABI Step-One Plus (Applied Biosystems) real-time PCR instrument using the allelic discrimination method according to manufacturer’s instruction [12]. All probes were pre-designed SNP Genotyping Assay and purchased from Applied Biosystems. For PiS, the rs1758 (assay ID: C_594695_20) probe was used; for PiZ allele, the rs28929474 (assay ID: C_34508510_10) was used; for the PiM2/M4 allele, the rs709932 (assay ID: C_2895146_20) probe was used and finally for the PiNull allele, rs28929473 (assay ID: C_63321235_20) was used.
Hepatocyte isolation and culture

With approval from the local ethics committees (Dnr: 2010/678-31/3) liver tissue used for hepatocyte isolation was acquired with informed written consent from patients undergoing liver resection surgery following primary/secondary tumors or explanted livers from A1ATD patients being liver transplanted. Also one of the control liver tissues was obtained from one donor liver unsuitable for transplantation. The isolation process followed previously established and standardized method of three-step collagenase perfusion technique [13, 14]. Cell recovery and viability were determined using trypan blue exclusion method. Isolated primary human hepatocytes were cultured on matrigel matrix derived from Engelbreth-Holm-Swarm sarcoma [15]. Cells were cultured in William’s E medium (Sigma-Aldrich, Stockholm, Sweden) supplemented with HEPES (25mM), glutamine (2mM) insulin (10mM), dexamethasone (10mM), amphotericin B and gentamicin and plated in 12 well plates (Corning Life Sciences, Tewksbury, MA) at a density of 7.5x10^5 cells per well. The hepatocytes were cultured under standard culture conditions in 37˚C incubator with 5% CO₂.

A1AT treatment of primary human hepatocytes

Hepatocytes were isolated and plated day 0. The culture plates were divided into two groups, the first group was only treated with purified A1AT and the second group was treated with purified A1AT and subsequently co-treated with 10 ng/ml OSM (PeproTech inc. Rocky Hill, NJ, USA) the final 24 hours of culture. Treatment with purified A1AT (Prolastina®; Grifols, Barcelona, Spain) was started day 1 of culture and continued through day 5. The purified A1AT (final well concentration of 1, 3.5, 7 and 10 mg/ml) was mixed together with culture media and used to treat the cells daily.

Human lung tissue

Surgical lung explants from end-stage PiZZ A1AT emphysema cases with A1AT augmentation therapy (n = 10) and without A1AT therapy (n = 4) were retrieved from the Institute of Pathology of Hannover Medical School with the approval of the Hannover Medical School Ethics Committee (No. 2702–2015).

Gene expression analysis was performed as described previously [16–18]. Briefly, after immunohistochemical and histological evaluation, the specimens were cut into 10µm thick sections and suspended in a proteinase K digestion solution. After overnight incubation RNA was isolated using phenol-chloroform extraction, followed by ethanol precipitation [16]. cDNA was generated from 10µl of RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), as described in the manufacturer’s guidelines. Following, cDNA was preamplified with nonrandom PCR primers and PreAmp MasterMix (Applied Biosystems) to lower CT values by 14 PCR cycles [19]. For the subsequent quantitative real-time PCR (TaqMan 7500 Real-Time PCR system, (Applied Biosystems)), the preamplified cDNA was equilibrated with TaqMan Gene Expression Master Mix and the individual TaqMan Gene Expression mixture. Total expression of SERPINA1 was analysed using expression of the gene DNA-directed RNA polymerase II subunit RPB1 (Polr2a/POLR2A) as an endogenous reference gene.

Human adherent PBMCs

Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood of five healthy volunteers using Lymphosep discontinuous gradient centrifugation, according to the manufacturer’s instructions as previously described [20]. PBMCs were resuspended in RPMI
1640 with 2 mM N-acetyl-L-alanyl-L-glutamine (Gibco, Thermo Fisher Scientific, Grand Island, NY) containing supplements of 1% nonessential amino acids (Gibco), 2% sodium pyruvate (Gibco), and 20 mM HEPES (Gibco) and plated at a density of 6×10^6 cells/ml (12 well plates). Cells were incubated for 75 min at 37˚C and 5% CO₂ to allow monocytes to adhere to the cell culture plates. Afterwards, non-adherent cells were removed by washing with 1X DPBS containing Mg2+ and Ca2+ (Life Technologies), and fresh medium without FCS was added for 24 hours. Adherent PBMCs were treated with 1mg/ml A1AT (Zemaira, CSL Behring, King of Prussia, PA) alone or together with LPS (1μg/ml) (Sigma) for additional 24 hours.

**mRNA expression**

Total RNA was extracted using the TRIzol® reagent (Invitrogen, Carlsbad, CA) or the RNeasy Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. RNA was reverse-transcribed using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Thermo Fisher Scientific, Carlsbad, CA) into cDNA. The cDNA was diluted and mixed with TaqMan® assays specific for cyclophilin A (PPIA, Hs99999904_m1), HPRT (Hs02800695_m1) A1AT (SERPINA1, Hs01097800_m1 or Hs00165475_m1) CYP7A1 (CYP7A1, Hs00167982_m1), AFP (AFP, Hs00173490_m1), Ki67 (MKI67, Hs01032443_m1), pcna (PCNA, Hs00427214_g1) and caspase-3 (CASP3, Hs00234387_m1) containing primers and hydrolysis probes. Quantitative real-time PCR was performed on an ABI Step-One Plus (Applied Biosystems) instrument. The relative mRNA expression was calculated according to the ΔΔct cycle threshold method using StepOne software with HPRT as reference gene or by a modified ΔΔct cycle threshold method using cyclophilin A (PPIA) as a reference gene as described in [21].

**Human liver tissue**

Paraffin embedded tissue from 6 explanted PiZZ livers was collected and mounted in a tissue array system. Also, liver tissue from 13 previous cases of explanted or resected material was used as an A1AT proficient reference. All sections were stained for Ki67 by automated systems at the Karolinska University Hospital, the Department of Pathology. Antibodies were visualized using diaminobenzidine and sections were counterstained with hematoxylin. At least three or as many as necessary fields to surpass 1000 cells were counted per case. For all cases Ki67 positive hepatocytes and non-parenchymal cells (NPC) were identified and counted. Average number of hepatocytes counted per case was 1405 cell for proficient cases (n = 13) and 1273 for deficient cases (n = 6). Percentage Ki67 positive hepatocytes was calculated as Ki67 positive hepatocytes in all fields divided by all counted hepatocytes per case.

**Statistical analysis**

Statistical analysis was performed in Prism version 6 (Graphpad Software Inc., San Diego, CA, USA). Non-parametric Kruskal-Wallis one-way ANOVA on ranks was used for multiple group comparisons. Mann-Whitney U test for comparison between two groups or Wilcoxon test where applicable as normality could not be assumed. Values are reported as median with range. P values below 0.05 were considered significant and n values are reported in figures. Bars in boxplots represent medians and + symbol represent mean.

**Results**

In total, liver tissue from 15 individuals (7 females and 8 males) was used for hepatocyte isolation Table 1. The median age was 60.5 years (range 18–64, n = 6) for the deficient group and
44 years (range 5–76, n = 9) for the proficient group. Four patients underwent liver transplantation due to A1ATD. One patient with a homozygous ZZ mutation and one patient previously diagnosed as homozygous ZZ using isoelectric focusing were identified. Moreover, two samples were heterozygous Z. Additionally, one patient had a heterozygous S mutation and underwent liver transplantation. Remaining A1AT proficient samples showed no amplification for the Z or S mutations.

Purified A1AT decreases the mRNA expression of SERPINA1 in primary human hepatocytes

To evaluate the putative effect of exogenous A1AT, mRNA from proficient and deficient hepatocytes treated with A1AT was analyzed for SERPINA1 expression levels and compared to untreated controls. As shown in (Fig 1A) a significant decrease was detected in SERPINA1 mRNA expression following treatment with exogenous purified A1AT compared to untreated cells. Exogenous A1AT reduced SERPINA1 expression in a dose-dependent manner.

To further analyze the effects of purified A1AT on hepatocytes with high expression of SERPINA1—OSM a potent inducer of SERPINA1 was employed. Addition of OSM resulted in an increase of SERPINA1 expression (P = 0.0154, Mann-Whitney U test) (Fig 1B). The highly up-regulated SERPINA1 was reduced using purified A1AT. Notably, the effect of exogenous A1AT on SERPINA1 expression was more pronounced in OSM-activated hepatocytes than in unstimulated cells.

SERPINA1 mRNA in lung tissue from PiZZ patients with and without augmentation therapy

We questioned if a similar reduction in SERPINA1 gene expression can be observed in lung tissue from A1AT treated PiZZ emphysema patients as we found in hepatocyte cultures. As shown in (Fig 2) median expression of SERPINA1 was 0.42 (range 0.075–1.09) in lung tissue samples from PiZZ patients with augmentation therapy (n = 10) compared to patients without
therapy 1.12 (range 0.54–3.42) (n = 4), although, this difference did not reach statistical significance (Median, P = 0.0539, Mann-Whitney U test).

**Effects of exogenous A1AT protein on SERPINA1 mRNA in adherent PBMCs, in vitro**

Investigation of a different cell type other than hepatocytes was carried out to test whether the inhibitory effect of exogenous A1AT on SERPINA1 is a more general phenomenon (Fig 3). Similarly as in hepatocytes, treatment of PBMCs with purified A1AT (1mg/ml) reduced SERPINA1 mRNA expression from 15.48 (range 11.92–18.31) to 10.52 (range 7.92–13.51) (median, n = 7, P = 0.0156, Wilcoxon test). Furthermore, purified A1AT reduced SERPINA1 expression from 31.38 (28.05–41.37) to 22.39 (18.91–23.96) in LPS-stimulated PBMCs. Indeed, effect of exogenous A1AT on SERPINA1 expression was again more pronounced in activated PBMCs than in unstimulated cells (median, range), n = 7, P = 0.0156, Wilcoxon test).

**mRNA expression in A1AT-deficient vs. proficient hepatocytes**

It has been speculated that there is a higher hepatocellular turnover in a mouse model of A1AT deficiency [22]. Therefore, comparison between A1AT-deficient and proficient hepatocytes was conducted regarding basal levels of SERPINA1 and upregulation of cell turnover. As shown in (Fig 4), no differences were detected in mRNA expression of SERPINA1, CYP7A1, Ki67, PCNA and AFP between proficient and deficient cells. However, the expression of CASP3 was higher in deficient cells (P = 0.0177, Mann-Whitney U test).

**Liver immunohistochemistry**

Liver tissues from six explanted PiZZ livers were collected and cell proliferation was measured by Ki67 staining in comparison to A1AT proficient tissues. In the PiZZ group the percentage of hepatocytes positive for Ki67 was 2.75% compared to 0.78% in the proficient
group (median, P = 0.0285, Mann-Whitney U test) (Fig 5). Non-parenchymal cells showed no difference.

**Discussion**

Our data provide new evidence that exogenous purified human plasma A1AT protein can lower expression of SERPINA1 gene in human primary hepatocytes and human adherent PBMCs, in vitro. Noticeably, this effect of exogenous A1AT was observed in hepatocytes isolated from both A1AT proficient and deficient patients as well as in human PBMCs from PiMM healthy individuals (Fig 3). Similar trends were also detected in lung tissues obtained from a small cohort of PiZZ A1ATD emphysema patients receiving augmentation therapy relative to those without therapy (Fig 2). It is also important to point out that inhibitory effect of
Exogenous A1AT on SERPINA1 expression was even more pronounced in cells activated with inflammatory stimuli. Altogether, our findings highlight the more complex benefits of A1AT therapy than just ameliorating protease imbalance in A1AT deficiency. Moreover, our data support the hypothesis that therapy with A1AT not only augments missing protein levels in PiZZ patients but also reduces expression of defective Z-A1AT protein. This may have important implications during acute phase reactions when increased synthesis of Z-A1AT provides favorable conditions for defective Z-A1AT polymerization and intracellular accumulation.

Expression of selected genes reflecting function, damage and proliferation between proficient and deficient cells were similar. There was a large overlap of SERPINA1 expression between proficient and deficient cells suggesting that production of mutant Z-A1AT is equal to non-mutant M-A1AT protein. This latter confirms that Z-A1AT pathologies involving reduced protein secretion due to retention of mutant protein rather than its impaired production [23]. On the other hand, we found a higher CASP3 expression in A1AT deficient cells compared to proficient cells in line with results reported from PiZ transgenic mice [22]. Higher CASP3 expression can be indicative of enhanced apoptotic activity and turnover among the deficient cells resulting from Z-A1AT protein aggregation. In murine models, it has been reported that A1AT could ameliorate acute liver failure through decreased apoptosis and reduced caspase-3 activity [24]. A1AT has also displayed pro-survival and anti-apoptotic effect through caspase-3 inhibition in murine lung endothelial cell, reducing alveolar wall destruction [25]. These are important factors to consider in the clinical setting where restoration of adequate levels of circulating A1AT could alleviate cellular damage.

Hepatocyte proliferation was examined in explanted liver tissue from PiZZ patients undergoing liver transplantation. The extent of cirrhosis was evident. The pathology and cirrhosis was coupled with increased proliferation as revealed by Ki67 staining. These results are
consistent with findings from male PiZ transgenic mice, where increased hepatocellular proliferation has been reported [22]. Elevated levels of CASP3 and increased proliferation evident by Ki67 staining in the PiZZ deficient liver are pointing towards a higher cell turnover. We speculate that the deficient PiZZ liver is a suitable candidate for hepatocyte transplantation as the increased cell turnover can be beneficial for repopulation by transplanted healthy PiMM
hepatocytes. Transplanting a small fraction of PiMM donor hepatocytes in A1ATD individuals could potentially downregulate the production of Z-A1AT. Functioning circulating M-A1AT has been reported in a hepatocyte transplanted patient with A1AT deficiency [26]. Donor cells would experience a growth advantage as compared to native cells producing faulty protein [22].
The efficacy of augmentation therapy has been debated and focus has mainly been reserved for its protective effect on the lungs. The effects of augmentation therapy on liver status are generally not explored. Although A1ATD patients report a subjective improvement and better quality of life, hesitation in initiating the therapy and difficulties justifying the high cost and lifelong repeated hospital visits for intravenous treatment remain [1, 27]. In this context, studies of hepatic effects of augmentation therapy are important in understanding unknown aspects of the disease and therapies.

Small groups were a hindrance in statistical evaluations. Another limitation is the absence of Z-A1AT levels in culture media following treatment with M-A1AT (Prolastina®). We were not able to separate between exogenously added M-A1AT and Z-A1AT released by hepatocytes in culture media. Effort can be directed toward studies of SERPINA1 expression and A1AT content in liver biopsies from patients receiving augmentation therapy. Unfortunately, such material was not available to us.

Although our results are preclinical, if confirmed by further studies, they could have several implications for A1ATD patients. New long term treatment regimen aiming at reducing or preventing liver disease, as well as lung disease could have a tremendous impact on health care for A1ATD patients.

Conclusions
In conclusion, our data provide evidence that plasma purified A1AT can reduce SERPINA1 gene expression. This effect was observed in both deficient and proficient cells suggesting a beneficial effect of augmentation therapy for liver that should be evaluated further.

Author Contributions
Conceptualization: AK RG S. Strom SJ GN EE.
Data curation: AK HJ HZ SJ L-MM KK CJ KS B-GE DJ EE.
Formal analysis: AK HJ SJ EE.
Funding acquisition: SJ B-GE EE.
Investigation: AK HJ HZ L-MM DJ EE.
Methodology: AK HJ HZ L-MM S. Strom EE.
Project administration: AK EE.
Resources: AK HJ HZ S. Salipalli L-MM KK RG S. Strom B-GE DJ SJ GN EE.
Supervision: GN EE.
Validation: AK GN EE.
Visualization: AK.
Writing – original draft: AK SJ EE.
Writing – review & editing: AK HJ HZ S. Salipalli L-MM KK RG S. Strom B-GE DJ SJ GN EE.
References
1. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005; 365(9478):2225–36. https://doi.org/10.1016/S0140-6736(05)66781-5 PMID: 15978931
2. Lomas DA, Mahadeva R. alpha-1-Antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest. 2002; 110(11):1585–90. https://doi.org/10.1172/JCI16782 PMID: 12464660

3. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976.

4. American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003; 168(7):818–900. Epub 2003/10/03. https://doi.org/10.1164/rccm.168.7.818 PMID: 14522813

5. Carey EJ, Iyer VN, Nelson DR, Nguyen JH, Krowka MJ. Outcomes for recipients of liver transplantation for alpha1-antitrypsin deficiency-related cirrhosis. Liver Transpl. 2013; 19(12):1370–6. https://doi.org/10.1002/lt.23744 PMID: 24019185

6. Teckman J, Mangalat N. Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions. Expert Rev Gastroenterol Hepatol. 2015; 9(2):261–8. https://doi.org/10.1586/17474124.2014.943187 PMID: 25066184

7. Larsson C. Natural History and Life Expectancy in Severe Alpha1-Antitrypsin Deficiency, PI Z. Acta Med Scand. 1978; 204(1–6):345–51.

8. Berg NO, Eriksson S. Liver disease in adults with alpha-1-antitrypsin deficiency. N Engl J Med. 1972; 287(25):1264–7. https://doi.org/10.1056/NEJM197212212872502 PMID: 4117996

9. Eriksson S. Alpha-1 antitrypsin deficiency and liver cirrhosis in adults. An analysis of 35 Swedish autopsied cases. Acta Med Scand. 1987; 221(5):461–7. PMID: 3496734

10. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest. 1990; 85(5):1343–52. https://doi.org/10.1172/JCI114578 PMID: 2185272

11. Aggarwal N, Koepke J, Matamala N, Martinez-Delgado B, Martinez MT, Golpon H, et al. Alpha-1 Antitrypsin Regulates Transcriptional Levels of Serine Proteases in Blood Mononuclear Cells. Am J Respir Crit Care Med. 2016; 193(9):1065–7. https://doi.org/10.1164/rccm.201510-2062LE PMID: 27128707

12. Bartels CL, Marchetti AL, Highsmith EW, Tsongalis GJ. Real time PCR detection of the PI* Z and PI* S mutations associated with alpha1 antitrypsin deficiency. Am J Transl Res. 2009; 1(4):406. PMID: 19956452

13. Jorns C, Ellis EC, Nowak G, Fischer B, Nemeth A, Strom SC, et al. Hepatocyte transplantation for inherited metabolic diseases of the liver. J Intern Med. 2012; 272(3):201–23. https://doi.org/10.1111/j.1365-2796.2012.02574.x PMID: 22789058

14. Gramignoli R, Green ML, Tahan V, Dorko K, Skvorak KJ, Marongiu F, et al. Development and application of purified tissue dissociation enzyme mixtures for human hepatocyte isolation. Cell Transplant. 2012; 21(6):1245–60. https://doi.org/10.3727/096368911X600939 PMID: 22080793

15. Kleinman HK. Preparation of basement membrane components from EHS tumors. Current protocols in cell biology / editorial board, Juan S Bonifacino [et al]. 2001; Chapter 10.

16. Jonigk D, Merk M, Hussein K, Maegel L, Theophile K, Muth M, et al. Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol. 2011; 178(2):599–608. https://doi.org/10.1016/j.ajpath.2010.10.032 PMID: 21281792

17. Jonigk D, Modde F, Bockmeyer CL, Becker JU, Lehmann U. Optimized RNA extraction from non-deparaffinized, laser-microdissected material. Methods Mol Biol. 2011; 755:67–75. https://doi.org/10.1007/978-1-61779-163-5_5 PMID: 21761294

18. Izykowski N, Kuehnem M, Hussein K, Mitschke K, Gunn M, Janciuskiene S, et al. Organizing pneumonia in mice and men. J Transl Med. 2016; 14(1):169. https://doi.org/10.1186/s12967-016-0933-6 PMID: 27282780

19. Theophile K, Jonigk D, Kreipe H, Bock O. Amplification of mRNA from laser-microdissected single or clustered cells in formalin-fixed and paraffin-embedded tissues for application in quantitative real-time PCR. Diagn Mol Pathol. 2008; 17(2):101–6. https://doi.org/10.1097/PDM.0b013e318163f26e PMID: 18382351

20. Frenzel E, Wrenger S, Immenschuh S, Koczulla R, Mahadeva R, Deeg HJ, et al. Acute-phase protein alpha1-antitrypsin—a novel regulator of angiopoietin-like protein 4 transcription and secretion. J Immunol. 2014; 192(11):5354–62. https://doi.org/10.4049/jimmunol.1400378 PMID: 24760148

21. Nguyen TM, Sawyer JK, Kelley KL, Davis MA, Kent CR, Rudel LL. ACAT2 and ABCG5/G8 are both required for efficient cholesterol absorption in mice: evidence from thoracic lymph duct cannulation. J Lipid Res. 2012; 53(8):1598–609. https://doi.org/10.1194/jlr.M026823 PMID: 22669916

22. Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of alpha1-antitrypsin deficiency. Hepatology. 2004; 39(4):1048–55. Epub 2004/04/02. https://doi.org/10.1002/hep.20118 PMID: 15057909
23. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992; 357(6379):605–7. https://doi.org/10.1038/357605a0 PMID: 1608473

24. Jedicke N, Struever N, Aggrawal N, Welte T, Manns MP, Malek NP, et al. alpha-1-antitrypsin inhibits acute liver failure in mice. Hepatology. 2014; 59(6):2299–308. Epub 2014/01/23. https://doi.org/10.1002/hep.27024 PMID: 24449466

25. Petracek I, Fijalkowska I, Medler TR, Skirball J, Cruz P, Zhen L, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol. 2006; 169(4):1155–66.

26. Strom SC, Fisher RA, Thompson MT, Sanyal AJ, Cole PE, Ham JM, et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation. 1997; 63(4):559–69. Epub 1997/02/27. PMID: 9047152

27. Piitulainen E, Bernspång E, Björkman S, Berntorp E. Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human 1-antitrypsin. Eur J Clin Pharmacol. 2003; 59(2):151–6. https://doi.org/10.1007/s00228-003-0589-z PMID: 12728289